Archived Comments for:
Ciprofibrate therapy in patients with hypertriglyceridemia and low high density lipoprotein (HDL)-cholesterol: greater reduction of non-HDL cholesterol in subjects with excess body weight (The CIPROAMLAT study)
Homocysteine as a competitive inhibitor of ciprofibrate for PPAR alpha and gamma
Melvin Hayden, Department of Family and Community Medicine University of Missouri
29 July 2004
Congratulations on an excellent study and publication. I really enjoyed this well written paper and viewing the results of this study.
Homocysteine has been found to be a competitive inhibitor of PPAR alpha and gamma recently in our laboratory and may be playing an important role in your observations especially in those with BMI greater than 25 as compared to those with a BMI less than 25. I would suggest that the data might be changed by the addition of folic acid in these patients to lower the homocysteine and reexamine the results if possible.
It would be exciting if you could examine the levels of homocysteine and see if there is any correlation to your exciting published results.
Sincerely,
M.R. Hayden, M.D.
mrh29@usmo.com
See paper and references:
Homocysteine and reactive oxygen species in metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: The pleiotropic effects of folate supplementation
Melvin R Hayden, Suresh C Tyagi
Nutrition Journal 2004, 3:4 (10 May 2004)
References: [71-74] (figure 5)
We look forward to your reply and ideas regarding this comment. M.R. Hayden, MD
Cardiovascular Diabetology
Homocysteine as a competitive inhibitor of ciprofibrate for PPAR alpha and gamma
29 July 2004
Congratulations on an excellent study and publication. I really enjoyed this well written paper and viewing the results of this study.
Homocysteine has been found to be a competitive inhibitor of PPAR alpha and gamma recently in our laboratory and may be playing an important role in your observations especially in those with BMI greater than 25 as compared to those with a BMI less than 25. I would suggest that the data might be changed by the addition of folic acid in these patients to lower the homocysteine and reexamine the results if possible.
It would be exciting if you could examine the levels of homocysteine and see if there is any correlation to your exciting published results.
Sincerely,
M.R. Hayden, M.D.
mrh29@usmo.com
See paper and references:
Homocysteine and reactive oxygen species in metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: The pleiotropic effects of folate supplementation
Melvin R Hayden, Suresh C Tyagi
Nutrition Journal 2004, 3:4 (10 May 2004)
References: [71-74] (figure 5)
We look forward to your reply and ideas regarding this comment. M.R. Hayden, MD
Competing interests
There are no competing interests